Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR

Itolizumab was associated with high clinical response rates at Day 15 and 29​Responders were able to taper steroids by 70% at Day 29 and 99% at Day 169​Itolizumab being evaluated in pivotal Phase 3 EQUATOR study in first-line acute graft-versus-host diseaseLA JOLLA, Calif.--(BUSINESS WIRE)--$EQ #GVHD--Equillium, Inc...

Related Keywords

United States ,American ,John Koreth ,Michael Moore ,Eq Gvhd Equillium Inc ,Biocon ,Harvard Medical School ,Nasdaq ,International Blood Marrow Transplant Research ,Exchange Commission ,Ono Pharmaceutical Co Ltd ,Equillium Inc ,Head Of Corporate Communications ,Dana Farber Cancer Institute ,Tandem Meetings ,American Society ,Cellular Therapy ,International Blood ,Marrow Transplant ,Final Safety ,Efficacy Results ,Open Label Study Evaluating Itolizumab ,Novel Targeted ,Newly Diagnosed Acute Graft Versus Host Disease ,Oral Abstract ,Graft Versus Host Disease ,Biocon Limited ,Private Securities Litigation Reform Act ,Investor Relations Officer ,Corporate Communications ,